Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 423-432

  Morrissey, Colm ^a   Gallis, Byron ^a   Solazzi, Jeffrey W ^a   Kim, Byung Ju ^a   Gulati, Roman ^a   Vakar Lopez, Funda ^b   Goodlett, David R ^a   Vessella, Robert L ^a   Sasaki, Tomikazu ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Androgen receptor; Apoptosis; Artemisinin; Cell cycle; Dimer; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ARTEMISININ DERIVATIVE; CYCLIN D1; DIHYDROARTEMISININ DERIVATIVE; DIMER; MYC PROTEIN; PROSTATE SPECIFIC ANTIGEN; SURVIVIN; TRANSFERRIN RECEPTOR;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; GROWTH DISORDER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SOFT TISSUE METASTASIS; TUMOR XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; HUMANS; IRON; MALE; PROSTATIC NEOPLASMS; RECEPTORS, TRANSFERRIN;

EID: 77949356490     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328336f57b     Document Type: Article

References (33)

1. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18:767-773.
2. Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, Singh NP, et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 2009; 274:290-298.
3. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem 2004; 47:1299-1301.
4. Nakase I, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 2008; 354:28-33.
5. Duffy PE, Mutabingwa TK. Drug combinations for malaria: time to ACT? Lancet 2004; 363:3-4.
6. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228:1049-1055.
7. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002; 32:1655-1660.
8. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284:2203-2213.
9. Stockwin LH, Han B, Yu SX, Hollingshead MG, El Sohly MA, Gul W, et al. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 2009; 125:1266-1275.
10. Cai HH, Cai J, Yang PH. Electrochemical activity of holotransferrin and its electrocatalysis-mediated process of artemisinin. Bioorg Med Chem Lett 2009; 19:863-866.
11. Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, et al. Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorg Med Chem 2009; 17:741-751.
12. Posner GH, Paik IH, Sur S, McRiner AJ, Borstnik K, Xie S, et al. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J Med Chem 2003; 46:1060-1065.
13. Alagbala AA, McRiner AJ, Borstnik K, Labonte T, Chang W, D'Angelo JG, et al. Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. J Med Chem 2006; 49:7836-7842.
14. Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis 2008; 25:377-388.
15. Brubaker KD, Brown LG, Vessella RL, Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 2006; 6:15.
16. Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005; 65:1710-1718.
17. Brubaker KD, Corey E, Brown LG, Vessella RL. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151-160.
18. Kokontis J, Takakura K, Hay N, Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54:1566-1573.
19. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998; 16:1913-1920.
20. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60:4709-4713.
21. Niitsu Y, Kohgo Y, Nishisato T, Kondo H, Kato J, Urushizaki Y, et al. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987; 153:239-243.
22. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol 1983; 36:539-545.
23. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995; 91:41-46.
24. Guntupalli JN, Padala S, Gummuluri AV, Muktineni RK, Byreddy SR, Sreerama L, et al. Trace elemental analysis of normal, benign hypertrophic and cancerous tissues of the prostate gland using the particle-induced X-ray emission technique. Eur J Cancer Prev 2007; 16:108-115.
25. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004; 37:998-1009.
26. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008; 7:2736-2745.
27. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3:917-921.
28. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995; 20:187-190.
29. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000; 19:1346-1353.
30. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, et al. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005; 63:369-384.
31. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 2003; 112:1724-1731.
32. Syed V, Mak P, Du C, Balaji KC. Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1. J Cell Biochem 2008; 104:82-95.
33. Cleutjens KB, van Eekelen CC, van Der Korput HA, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996; 271:6379-6388.